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Abstract 
Introduction: The presence of a chronic total occlusion (CTO) is associated with an increased risk of 
ventricular arrhythmias.  
Areas covered: This review provides an overview of the relationship between CTO and ventricular 
arrhythmias, arrhythmogenic mechanisms, and the effect of revascularization.  
Expert opinion: Studies in recipients of an implantable cardioverter-defibrillator (ICD) have shown 
that a CTO is an independent predictor of appropriate ICD therapy. The myocardial territory supplied 
by a CTO is a pro-arrhythmogenic milieu characterized by scar tissue, large scar border zone, 
hibernating myocardium, residual ischemia despite collaterals, areas of slow conduction, and 
heterogeneity in repolarization. Restoring coronary flow by revascularization might be associated 
with electrical homogenization as reflected by a decrease in QT(c) dispersion, decrease in T wave 
peak-to-end interval, reduction of late potentials, and decrease in scar border zone area. Future 
research should explore whether CTO revascularization results in a lower burden of ventricular 
arrhythmias. Furthermore, risk stratification of CTO patients without severe LV dysfunction is 
interesting to identify potential ICD candidates. Potential tools for risk stratification are the use of 
electrocardiographic parameters, body surface mapping, electrophysiological study, and close 
rhythm monitoring using an insertable cardiac monitor.  
 
Keywords: Chronic total occlusion, Coronary artery disease, Implantable cardioverter-defibrillator, 
Percutaneous coronary intervention, Sudden cardiac death, Ventricular arrhythmias 
 
Article highlights 
• A CTO is associated with an increased risk of ventricular arrhythmias. 
• The territory supplied by a CTO is a proarrhythmogenic milieu characterized by scar tissue, large 
scar border zone, hibernating myocardium, residual ischemia despite collaterals, areas of slow 
conduction, and heterogeneity in repolarization. 
•  Restoring coronary flow by CTO PCI is associated with electrical homogenization as reflected by 
a decrease in QT(c) dispersion, decrease in T wave peak-to-end interval, reduction of late 
potentials, and decrease in scar border zone area. 
• Future studies should focus on the effect of CTO PCI and better risk stratification of patients with 
a CTO for a prophylactic ICD.  
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1. Introduction 
The presence of a chronic total occlusion (CTO) is associated with an increased risk of sudden cardiac 
death (SCD) [1-4]. This seems to be mainly driven by a higher risk of ventricular arrhythmias (VAs) 
[1,5-8]. There is emerging clinical evidence that the presence of a CTO has a proarrhythmic effect [9-
11]. This observation is clinically relevant as a CTO is a common finding (approximately 20%) in 
patients with coronary artery disease [1,12-15]. Technicall advances in percutaneous CTO 
revascularization has resulted in higher success rates (>90%) and lower complication rates in high 
volume and dedicated centers [16]. Successful CTO revascularization has been associated with a 
reduction in angina, positive left ventricular (LV) remodeling, and improvement in quality of life [17-
23]. However, the beneficial prognostic role of a CTO revascularization is still under debate [22,24]. 
There is a paucity of randomized studies which have focused on a prognostic benefit in comparison 
to medical management [16,25-27]. Currently, factors that are taken into account when selecting 
patients for a CTO revascularization, include symptomatic angina, extent of ischemia, and degree of 
myocardial viability [28]. Considering the increased vulnerability for VA in patients with CTO, more 
refined risk stratification is necessary to identify potential candidates for an implantable 
cardioverter-defibrillator (ICD). The current ICD recommendations for primary prevention are largely 
based on LV ejection fraction (Figure 1) [29-31]. 
The aims of this review are: 1) to provide an overview of the clinical evidence demonstrating 
a relationship between CTO and VA; 2) to expand on the potential mechanisms for the increased VA 
susceptibility; 3) to evaluate the potential beneficial role of CTO revascularization on 
electrophysiological parameters; and 4) to discuss potential future research areas with regard to risk 
stratification. 
 
2. CTO and risk for ventricular arrhythmias 
2.1. CTO in ICD recipients 
The last decade, several studies have evaluated the association between CTO and the occurrence of 
VA in ICD recipients with coronary artery disease [5-8,32] (Table 1). One of the first studies was 
published in 2012 by Nombela-Franco et al (VACTO Primary Study) [6]. They evaluated in a single-
center cohort the impact of unrevascularized CTO on the occurrence of VA in 162 patients with 
ischemic cardiomyopathy and a primary prevention ICD. The presence of an unrevascularized CTO 
was an independent predictor of appropriate ICD therapy. In contrast, Raja et al. found that the 
presence of a CTO (revascularized or not) was not associated with a higher mortality or VA [32]. In 
this single-center study, 307 patients with ischemic cardiomyopathy and an ICD for primary 
prevention were included. The study population consisted of 114 patients with unrevascularized 
CTO, 99 patients with revascularized CTO, and 94 patients without CTO. During a median follow-up of 
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4.1 years, 17% died and 32% had at least one episode of appropriate ICD therapy. Presence of a CTO 
(irrespective of revascularization) was not associated with the risk of appropriate ICD therapy or 
mortality.  
 It is important to realize that patients who receive an ICD for primary prevention have severe 
LV dysfunction (LVEF <35%). Thus, abovementioned ICD studies evaluating the role of CTO and the 
occurrence of VA do not involve patients with preserved or midrange ejection fraction. Further 
insight is provided by studies evaluating the association between CTO and the occurrence of VA in 
patients who received an ICD for secondary prevention. Two studies have specifically evaluated the 
effect of a CTO on VA recurrence in survivors of SCD or sustained VA [5,7]. In a retrospective single-
center study, Yap et al. evaluated 217 patients with aborted SCD who received an ICD [7]. The 
proportion of patients with a LVEF <35% was 52%. Appropriate ICD therapy was higher in patients 
with CTO (37% versus 25% at 5 years). The presence of an unrevascularized CTO and LVEF <35% were 
independent predictors of appropriate ICD therapy. The results were confirmed by the large 
multicenter VACTO Secondary Study, which included 425 patients from 8 centers who received an 
ICD for secondary prevention [5]. The proportion of patients with a LVEF ≤40% was 63%. Appropriate 
ICD therapy was higher in patients with CTO (51% versus 36% at 4 years). Also, in this study the only 
independent predictors of appropriate ICD therapy were the presence of a CTO and LVEF. Among 
patients with CTO, renal dysfunction and LVEF <40% were independent factors associated with 
appropriate ICD therapy. Van Dongen et al. evaluated 722 patients with ischemic cardiomyopathy 
who received an ICD for primary and secondary prevention [33]. A CTO was an independent 
predictor of appropriate ICD therapy. Interestingly, primary prevention patients without a CTO 
experienced the lowest appropriate ICD therapy rate compared with primary prevention patients 
with a CTO and secondary prevention patients.  
 A meta-analysis by Wang et al. in 2018, included 6 studies evaluating the prognostic role of 
CTO with regard to appropriate ICD therapy [34]. The authors conclude that CTO was a predictor of 
VA in patients with ICD for secondary prevention (HR 1.96, 95% CI 1.55-2.48), but not for patients 
with an ICD for primary prevention (HR 1.84, 95% CI 0.63-5.33). This may suggest that in patients 
with already severe LV dysfunction, the presence of CTO does not give an incremental risk of VA. 
However, it is important to highlight that in patients with ICD for primary prevention only 1 of 3 
studies did not demonstrate a relationship between CTO and VA [32]. 
 
2.2. CTO in an infarct-related artery  
Some authors have suggested that a CTO in an infarct-related artery (IRA-CTO) may be a better 
predictor of VA than a CTO without a myocardial infarction in its territory (non-IRA-CTO) [9,11] (Table 
1). The lower arrhythmic risk of a non-IRA-CTO may be related the absence of a postinfarction scar. 
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An IRA-CTO is defined as a CTO associated with a previous myocardial infarction in the territory of 
the coronary artery. Evidence for a previous myocardial infarction is demonstrated by the presence 
of Q-waves in the electrogram and/or evidence of scar at imaging, such as clear wall motion 
abnormalities at echocardiogram or late gadolinium enhancement at cardiac MRI [9]. Using this 
definition approximately two thirds of patients with a CTO have an IRA-CTO [9,10]. Di Marco et al. 
performed a two-center study (n=342) including ischemic cardiomyopathy patients who received an 
ICD for primary or secondary prevention [10]. At least 1 CTO was present in 182 patients (53%) and at 
least one IRA-CTO was found in 161 patients (47%). An IRA-CTO was significantly more prevalent in 
patients with secondary prevention ICD as compared to primary prevention (62% versus 32%, 
P<0.001). Patients with IRA-CTO had higher proportions of appropriate ICD therapies (57% versus 
26%, P< 0.001) and appropriate ICD shocks (40% versus 17%, P < 0.001). Patients with a non-IRA-CTO 
had a similar risk of VA compared to those without CTO (HR 1.0, 95% CI 0.4-2.3, P=0.97). However, it 
is good to realize that the number of patients with a non-IRA-CTO was small (n=21), precluding 
strong statements that an IRA-CTO is more vulnerable to VA than a non-IRA-CTO. 
In 2018, Chi et al. performed a systematic review and meta-analysis examining the 
relationship between CTO and arrhythmic and mortality outcome [8]. Compared to patients without 
IRA-CTO (i.e., patients without CTO and patients with non-IRA-CTO), patients with IRA-CTO have a 
higher risk of VA or appropriate ICD therapy (HR, 2.47, 95% CI, 1.76-3.46), cardiac mortality (HR, 2.73, 
95% CI, 1.02-7.30), and all-cause mortality (HR, 1.69, 95% CI, 1.19-2.40).  
 
3. Proarrhythmogenic substrate in CTO territory  
Based on abovementioned clinical studies, there seems to be an increased risk of VA in patients with 
a CTO (Figure 2). In patients with  previous myocardial infarction, the mechanism of VA usually 
depends on a scar-related reentry circuit [35]. One study showed that the properties of spontaneous 
VA between patients with and without CTO is similar with respect to cycle length and type of onset. 
However, the coupling interval of the initiating beat is shorter in patients with CTO [5]. This suggest 
that the trigger or substrate is different in patients with a CTO.  
The scar border zone seems critical for the occurrence of VA. This zone consists of surviving 
cardiomyocytes interposed between fibrotic tissue and is characterized by areas of fractionation and 
activation delay [36,37]. Several studies using contrast-enhanced MRI have demonstrated that a 
larger scar border zone, as defined by infarct gray zone or peri-infarct zone, was associated with an 
increased risk of spontaneous and inducible VA in ICD recipients [38-40]. Electrophysiological 
mapping studies have shown that a CTO in an infarct-related artery was associated with a larger scar 
border zone (defined by bipolar voltage of 0.5-1.5 mV) in comparison to patients with no CTO in an 
infarct-related artery [11]. This large border zone may be associated with heterogenous ventricular 
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repolarization. After CTO revascularization there is immediate decrease in scar border zone area. 
Furthermore, there is improvement of markers of heterogeneity of repolarization as reflected by QT 
dispersion [41,42]. It is known that heterogenous ventricular repolarization is associated with an 
increased risk for ischemia-related VA after myocardial infarction [43]. Thus, a larger scar border 
zone may explain the increased vulnerability for VA in patients with IRA-CTO.  
The proarrhythmogenic milieu is further enhanced by the presence of chronic residual 
ischemia in the CTO territory despite the presence of collaterals. It is well-known that ischemia is an 
important trigger for VA. Collateral connections are observed in almost all CTOs and they have the 
capability to prevent myocardial necrosis [44]. Rentrop grade ≤1 collateral flow (poor collateral flow) 
varies between 10% to 28% depending on patient population [5,10]. Collateral function can develop 
to a similar functional level in patients after myocardial infarction with large areas of akinesia as it 
does in patients with normal preserved regional function [44,45]. During exercise, collaterals have 
limited functional reserve and most patients will experience ischemia due to coronary steal despite 
angiographically well-developed collaterals [45]. Using fraction flow reserve (FFR), Sachdeva et al. 
demonstrated that the majority of CTO patients have an ischemic FFR (<0.80), even those with 
severe regional dysfunction or well-developed collaterals [46]. Furthermore, resting ischemia was 
present in 78% of CTO patients despite a negative noninvasive stress test. These data suggest that 
the myocardium supplied by a CTO is chronically repetitive ischemic in a majority of patients. 
Sympathetic stimulation, for example during exercise, increases the difference in refractoriness in 
ischemic areas, potentially leading to regional conduction block and the propensity to reentrant 
arrhythmias [47].  
There is inconsistency with regard to the role of better collateral flow and the occurrence of 
VA. Some studies in patients with ICDs for primary prevention have shown a nonsignificant trend 
towards less VA in those with better collateral flow [6,9,10]. In contrast, the VACTO Secondary study 
demonstrated that good collateral flow (Rentrop grade 3) was associated with a higher incidence of 
VA in comparison to patients with less collateral flow (Rentrop grade ≤2 flow) (HR 1.54, 95% CI 1.04-
2.26) [5]. The increased susceptibility to VA in patients with good collateral flow can be explained by 
a greater amount of hibernating myocardium, especially in a peri-infarct area [46]. Contrast-
enhanced MRI studies have demonstrated less segmental transmurality and higher chance of 
improvement of dysfunctional segments after percutaneous coronary intervention (PCI) of a CTO 
with improving Rentrop grade [48,49]. Although this implies that a good collateral circulation is more 
likely to supply viable myocardium, this chronic hibernating myocardium is a potential 
pathophysiologic substrate for VA [50]. Hibernating myocardium displays abnormal and 
heterogeneous electrical properties and contributes to the formation of a substrate for reentry.  
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Chronic ischemia results in regional cellular remodeling including myocyte hypertrophy, 
interstitial fibrosis, and inhomogeneity of sympathetic innervation [47,51-53]. Furthermore, electrical 
remodeling occurs due to abnormal intracellular ionic homeostasis secondary to metabolic 
derangement and increased oxidative stress [54,55]. These changes may contribute to cardiac 
arrhythmogenesis. This remodeling process may take time and may explain the observation that 
there is a delay in the occurrence of VA after a myocardial infarction in CTO patients [10]. Thus, 
regional adaptations that promote myocyte survival in the setting of CTO may result in a substrate 
with enhanced susceptibility to VA.  
 
4. CTO revascularization lowers arrhythmic risk 
The rationale of CTO revascularization is that it relieves ischemia in the CTO territory by restoring 
coronary flow. Successful CTO PCI has been associated with reverse LV remodeling and improved 
quality of life [25,26,49]. Evidence that CTO PCI improves survival is largely based on observational 
cohort studies comparing patients with a successful and failed CTO PCI. A meta-analysis in 2015, 
including 25 observational studies, demonstrated a twofold higher risk of all-cause mortality in 
patients with a failed CTO PCI (odds ratio [OR] 1.92, 95% CI 1.59-2.33) in comparison to a successful 
CTO PCI [22]. However, a recent meta-analysis of 3 randomized controlled trials (i.e., EUROCTO, 
DECISION-CTO, REVASC) (N=1416) demonstrated that CTO PCI was not associated with a lower all-
cause mortality (OR 0.71, 95% 0.38-1.30) or cardiac mortality (OR 0.64, 95% CI 0.28-1.43) in 
comparison to medical therapy [56]. Thus, to verify the hypothesis that CTO PCI enhances survival a 
randomized controlled trial with appropriate sample size will be necessary.  
Data on the effect of CTO PCI on the incidence of VA is very limited. Recently, a multicenter 
observational study by Godino et al. (N=1162) demonstrated that a failed CTO PCI was associated 
with an almost threefold increased risk of SCD and/or sustained VA (HR 2.71, 95% CI 1.48-4.99), even 
after correcting for confounders such as LVEF [57]. The baseline LVEF in the study population was 
relatively high (53±10%). During a median follow-up of 6 years, the rate of arrhythmic events was 
7.5% and 2.5% (P<0.001) in the failed and successful CTO PCI, respectively. Interestingly, a subgroup 
analysis demonstrated that a failed CTO PCI in IRA-CTO was associated with a higher risk of 
SCD/sustained VA (HR 2.79, 95% CI 1.43-5.45, P=0.003). This was not the case for a failed CTO PCI in a 
non-IRA-CTO. Approximately half (55%) of all CTO PCI procedures were performed in an IRA-CTO.  
 The lower arrhythmic risk in patients with successful CTO PCI of an IRA-CTO may be related 
to elimination of myocardial ischemia in chronic hibernating myocardium, regional cellular 
remodeling, decrease in electrical heterogeneity, improvement of autonomic nervous activity, 
and/or lower dependency of collateral flow [47,57-59] (Figure 1). Van Dongen et al. performed the 
first systematic review and meta-analysis focusing on the effect of CTO PCI on electrocardiographic 
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parameters [41]. They included 8 studies incorporating 467 patients. After CTO PCI there was an 
improvement of several surrogate arrhythmic markers that reflect heterogeneity in depolarization 
and repolarization. Successful CTO PCI was associated with a decrease in QT dispersion (17 ms, 95% 
CI 11-24 ms) and QTc dispersion (19 ms, 95% CI 12-26 ms) within one day after PCI [60]. These effects 
remain stable at 6 months. Furthermore, there was a reduction of T-wave peak-to-end (Tp-e) interval 
in lead V2 and V5 within 48 after CTO PCI, also after correction for QTc interval (Tp-e/QTc) [61]. 
Finally, there was a decrease in the presence of late potentials after CTO PCI  [60].  
Interestingly, recent 3D electro-anatomically mapping studies demonstrated reduction of the 
area of the scar border zone after successful CTO PCI [42,62]. Yamashita et al. performed high-
density endocardial mapping during sinus rhythm before and 8 months after CTO PCI in 16 patients 
[42]. Thirteen patients had a successful CTO PCI and no restenosis; 3 patients had a failed CTO PCI or 
in-stent occlusion during follow-up. There was a significant reduction of border zone area (0.5-1.5 
mV) (-10.5 cm2 [-16.8 to -4.1], P=0.004) without a change in dense scar area (<0.5mV) in patients 
with a successful CTO PCI. Furthermore, a small study of 3 patients demonstrated that the reduction 
in border zone area occurs immediately after IRA-CTO PCI [62].  
Thus, based on abovementioned observations most electrophysiological parameters seem to 
improve immediately after CTO PCI. This suggests that electrophysiological properties in the CTO 
region can improve immediately after CTO PCI in contrast to mechanical properties (i.e., reverse 
remodeling). The combination of homogenization of repolarization, disappearance of late potentials, 
and reduction of scar border zone area may potentially reduce the vulnerability for VA in patients 
who have undergone successful CTO PCI. There is a lack of randomized trials which has focused on 
the incidence of VA or SCD.  
  
5. Conclusion 
A CTO seems to be associated with a higher risk of VA and mortality in ICD recipients. This increased 
arrhythmic risk may be related to the presence of a chronically hibernating myocardium in the CTO 
territory despite the presence of a well-developed collateral system. The limited available data on 
the effect of CTO PCI on electrophysiological parameters suggest that revascularization may provide 
immediate electrical stability. This is reflected by a decrease in heterogeneity in repolarization, 
reduction of late potentials, and decrease in scar border zone area. Further studies are necessary to 
evaluate whether CTO PCI renders patients less vulnerable to VA.  
 
6. Expert opinion 
SCD is a devastating consequence of a myocardial infarction. Previous studies have shown that 
systolic LV function is the most important predictor for future arrhythmic events. Patients with 
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ischemic cardiomyopathy and a LVEF <30-35% are candidates for a prophylactic ICD [29-31] (Figure 
1). However, in clinical practice we also encounter patients with CTO after an out-of-hospital cardiac 
arrest without severe LV dysfunction. Studies in patients who received an ICD for secondary 
prevention demonstrated that CTO and LVEF were independent predictors of appropriate ICD 
therapy [5,7]. The myocardial territory of a CTO is a proarrhythmogenic milieu characterized by scar 
tissue, large scar border zone, hibernating myocardium, residual ischemia despite collaterals, areas 
of slow conduction, and heterogeneity in repolarization. Restoring coronary flow by CTO PCI is 
associated with electrical homogenization. This is reflected by a decrease in QT dispersion, decrease 
in QTc dispersion, decrease in T wave peak-to-end interval, reduction of late potentials, and decrease 
in scar border zone area.  
These observations mandate further evaluation focused on several research areas. First, 
although a large observational study demonstrated that a successful CTO PCI was associated with a 
lower arrhythmic risk [57], an appropriately designed prospective study should explore whether 
revascularization of CTO reduces the risk of VA/SCD. In this respect, also surrogate markers of 
increased arrhythmic risk can be used as detailed in the systematic review of Van Dongen et al [41]. A 
randomized controlled trial will be difficult to conduct considering the low event rate of VA/SCD, 
thus, requiring a large sample size.  
Second, a CTO seems to identify patients who may benefit from a prophylactic ICD implant. 
Future studies should focus on refinement of risk stratification in this group, especially in those 
without severe LV dysfunction. Prospective studies evaluating the value of electrophysiological 
studies, contrast enhanced MRI, body surface mapping and long-term rhythm monitoring using 
implantable cardiac monitor (ICM) may be interesting [63]. Previously, the MUSTT study has shown 
that electrophysiologic testing in patients with coronary artery disease (90% with previous 
myocardial infarction), nonsustained VA and LVEF ≤40%, may identify patients who are at higher risk 
of arrhythmic death [64] (Figure 2). The likelihood of a randomized controlled ICD trial in this specific 
patient population seems low. The first step could be to study the VA inducibility before and after 
CTO PCI thereby using VA inducibility as a surrogate marker for future arrhythmic risk.  
The use of high-resolution body surface mapping to study heterogenous ventricular 
repolarization has been evaluated as a risk marker for arrhythmic events in post-myocardial 
infarction patients [65-67]. However, body surface mapping has not been studied in patients with a 
CTO.  
We expect that the decision to implant a prophylactic ICD in this population in the future will 
be based on a multiparametric analysis of different risk factors (e.g., unexplained syncope, repetitive 
nonsustained VA, extensive late gadolinium enhancement, inducible VA, markers of heterogenous 
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ventricular repolarization). Such a strategy is also employed in patients with hypertrophic 
cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome [30].   
 Considering the current knowledge on the increased risk of VA in patients with CTO, we 
expect more clinical studies confirming this relationship. Van Dongen et al. performed an interesting 
systematic review to identify electrophysiological parameters associated with increased VA risk 
which could be used for future research. Suggested parameters are fragmented QRS, late potentials, 
QT interval, QT dispersion, T-wave peak to end interval and T-wave alternans [41]. Future studies will 
identify which parameter will be useful and which not. In this respect, post-hoc analysis of 
randomized CTO PCI trials focusing on the effect of revascularization on electrocardiographic 
parameters may be interesting and feasible. Besides electrophysiologic parameters, another research 
area is to focus on VA burden in CTO patients by evaluating ectopy burden and incidence of 
nonsustained VA. For example, a Holter study before and after CTO PCI can establish whether 
revascularization reduces ectopy burden [41]. Furthermore, we are currently conducting a 
multicenter pilot study evaluating the incidence of VA using ICM in patients with CTO without severe 
LV dysfunction (Incidence of Ventricular Arrhythmias in patients with Chronic Total Occlusion 
Recanalization, VACTOR study, NCT03475888). The study population consists of patients with 
successful CTO PCI, failed CTO PCI and no CTO PCI attempt. This study will provide as more insight in 
the burden of (non)sustained VA in the different CTO populations. The results are to be expected in 
2023.  
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Figure legends 
Figure 1. Current recommendations for an ICD in patients with a CTO. 
Footnote. Based on the recommendations from the European Society of Cardiology (ESC), American 
College of Cardiology (ACC), American Heart Association (AHA) and Heart Rhythm Society (HRS) [29-
31]. Abbreviations: EP, electrophysiology study; ICD, implantable cardioverter-defibrillator; LV, left 
ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSVT, nonsustained 
ventricular tachycardia; NYHA, New York Heart Association; SCA, sudden cardiac arrest; VF, 
ventricular fibrillation; VT, ventricular tachycardia.  
 
Figure 2. Schematic overview of pro-arrhythmic effects of IRA-CTO and potential beneficial effects of 
CTO PCI. 
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Tables 
Table 1. CTO and appropriate ICD therapy/mortality in ICD recipients with coronary artery disease 
Study Ref. Year Primary vs 
secondary 
prevention 
(%) 
Study 
size  
(N) 
Age (years) Male 
(%) 
LVEF  
(%) 
CTO 
(%) 
Median 
FU  
(years) 
HR appropriate 
ICD therapy  
(95% CI) 
HR all-cause 
mortality  
(95% CI) 
Nombela-Franco [6] 2012 100/ 0  162 62±10 93 29±9 44 2.2 3.5 (1.5-8.3) 5.6 (1.4-21.8) 
Raja [32] 2015 100/ 0  307 63 (59-69) 100 29±7 37 4.1 0.8 (0.5-1.2) 1.7 (0.8-3.3) 
Di Marco [9]* 2017 100/ 0  108 59±10 90 25±5 31 2.8 3.64 (1.58-8.41) 1.49 (0.63-
3.56)** 
Di Marco [10]* 2017 48/ 52  342 64 (57-71) 89 30 (25-38) 47 2.8 2.3 (1.6-3.3) 1.6 (0.99-2.6)** 
Nombela-Franco [5] 2017 0/ 100 425 69 (61-76) 92 39±13 50 4.1 1.80 (1.30-2.50) 1.69 (1.04-2.73) 
Yap [7] 2017 0/ 100  217 63±10 86 NA 33 5.1 2.07 (1.23-3.50) 0.97 (0.51-1.87) 
Van Dongen  [33] 2018 74/ 26 722 66±11 84 30 (25-37) 33 4 1.39 (1.06-1.83) 1.27 (0.996-1.62) 
Continuous data are presented as mean±standard deviation or median (interquartile range). *The studies of Di Marco et al. focused on IRA-CTO [9,10]. All 
hazard ratios are based on multivariate analysis, except those marked with **. Abbreviations: CI, confidence interval; CTO, chronic total occlusion; HR, 
hazard ratio; LVEF, left ventricular ejection fraction; NA, not available. 
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